AbstractTwo multiple dose crossover pharmacokinetic studies were carried out to determine the steady‐state bioavailability of newly formulated generic propranolol HCl tablets relative to Inderal® tablets. In Study I, 24 healthy volunteers were dosed with 4 × 10mg test tablets, 1 × 40 mg test tablet, 4 × 10 mg Inderal tablets, and 40 mg of propranolol HCl in solution. In Study II, 24 healthy volunteers were dosed with 1 × 80 mg test tablet, 1 × 80 mg Inderal tablet, and 80 mg of propranolol HCl in solution. Both studies were of randomized design with each formulation administered every 8h for 15 doses. Serial plasma samples were obtained for 8 h after morning doses on Days 4 and 5 of each treatment period and assayed for propranolol using a validated HPLC method. Mean plasma concentration‐time data for test tablets and reference tablets were superimposable in both studies.Pharmacokinetic parameters from Days 4 and 5 were combined for statistical analysis since subjects were determined to have reached steady‐state. Mean AUC,Cmax,tmax, andCminvalues were not statistically different between test tablets and Inderal tablets in either study. Based on these findings, the test tablets demonstrated the same rate and extent of propranolol absorption as did corresponding Inderal® tablets. Therefore, the test tablets and Inderal® tablets were determined to be